Low-grade glioma (LGG) is a group of uncommon, WHO grade I and II, primary central nervous system tumors. They are usually inactive, but most of them will eventually become fatal high-grade gliomas. 2. In patients with large tumors, or those with extensive neurological symptoms, immediate surgical resection is the generally accepted treatment option. 3. For those tumors with transient symptoms, smaller size and no occupational manifestations, close observation follow-up is an option. Follow-up surgery can be performed after the patient develops accelerated tumor growth or tumor transformation to high-grade glioma, has refractory seizures, or progressive symptoms of neurological damage. In young patients (≤45 years), after total resection and containing favorable molecular features, such as IDH mutation and 1p19 combined deletion, we recommend observation and follow-up after surgery. Such patients will eventually relapse and will still require adjuvant therapy after progression. For tumors containing IDH wild type and those containing poor prognostic factors, such as residual tumor, age > 45 years, neurological deficit symptoms, and large tumors with occupying effects, we recommend adjuvant therapy immediately after surgery. 6. For patients who do not fall into one of the above two categories, the more risk factors there are, the more immediate postoperative adjuvant therapy is preferred. 7. For high-risk LGG, we recommend radiotherapy combined with chemotherapy rather than alone. PCV regimen is chosen for chemotherapy rather than temozolomide.